Weight-loss and diabetes medications keep turning up in kidney research, and the newest entry is a pooled analysis of semaglutide's three large outcome trials, published in 2026 in The Lancet Diabetes & Endocrinology. The headline number is a 16% lower risk of a kidney-related composite — and the finding matters for anyone with metabolic risk factors, which overlap heavily with kidney stone risk.
The three trials spanned different semaglutide doses and formulations — subcutaneous 1.0 mg and 2.4 mg, and oral 14 mg — and different populations, from people with overweight or obesity to people with type 2 diabetes and chronic kidney disease. Pooling them at the participant level, the analysis found 973 first kidney-composite events in the semaglutide group versus 1,134 in the placebo group. A narrower composite excluding cardiovascular death showed an even stronger signal (HR 0.80, 95% CI 0.69-0.92).
The mechanism is indirect and the relevance to stones is indirect too, but the overlap is real. Obesity and type 2 diabetes raise uric acid and the acidity of urine, both of which feed stone formation. Weight loss and better metabolic control tend to move those numbers in the stone-friendly direction. That does not make this a stone study — it is a kidney-function study — but it is a reminder that the metabolic picture and the stone picture are the same picture.
The foods that support weight and blood sugar also support stone prevention, and most of them measure low on oxalate:
| Food | Oxalate (mg) | Serving | Rating |
|---|---|---|---|
| Chicken breast, roasted | 0 mg | 4 oz | Safe |
| Salmon, cooked | 0 mg | 4 oz | Safe |
| Oatmeal, cooked | 2 mg | 1 cup | Safe |
| Banana | 6 mg | 1 medium | Safe |
| Watermelon | 2 mg | 1 cup cubed | Safe |
The pattern is the familiar one: lean protein, whole grains, and low-oxalate produce sit safe, while the metabolic variables — added sugar, excess calories, and the weight they produce — are what the plate is really managing.
For the food side, nothing changes: the stone and metabolic plans both reward the same plate — lean protein in moderation, whole grains, produce, and water. For the medication side, this is research worth knowing about, not an instruction. If you or a family member takes semaglutide and has a stone history, the right move is a conversation with the prescribing doctor, not a decision made from a pooled analysis.
See how oxalate values are measured and verified on our data methodology page.